LAVAL, QC, Sept. 8, 2017 /CNW Telbec/ - Prometic Life
Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that Pierre Laurin,
President and Chief Executive Officer, will provide a corporate overview at the Morgan Stanley Global Healthcare Conference, and
the Cantor Fitzgerald Global Healthcare Conference in September.
|
Cantor Fitzgerald Global Healthcare Conference
|
|
|
Date:
|
Monday, September 25
|
|
|
|
Time:
|
1:50pm Eastern Time
|
|
|
|
Location:
|
InterContinental New York Barclay
|
|
|
|
Webcast:
|
http://wsw.com/webcast/cantor6/pli/
|
About Prometic Life Sciences Inc.
Prometic Life Sciences Inc. (www.prometic.com)
is a long-established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics
and small-molecule drug development. Prometic is active in developing its own novel small-molecule therapeutic products targeting
unmet medical needs in the field of fibrosis, cancer and autoimmune diseases/inflammation. A number of plasma-derived and small
molecule products are under development for orphan drug indications. Prometic also offers its state-of-the-art technologies for
large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of
industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of
therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. Headquartered in
Laval (Canada), Prometic has R&D facilities in the UK, the U.S. and Canada, manufacturing
facilities in the UK and commercial activities in the U.S., Canada, Europe and Asia.
Forward Looking Statements
This press release contains forward-looking statements about Prometic's objectives, strategies and businesses that
involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about
the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions
turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Prometic's ability to develop,
manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to
pursue R&D projects, the successful and timely completion of clinical studies, the ability of Prometic to take advantage of
business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in
economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to
materially differ from our current expectations in Prometic's Annual Information Form for the year ended December 31, 2016, under the heading "Risk and Uncertainties related to Prometic's business". As a
result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any
forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless
required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.
SOURCE ProMetic Life Sciences Inc.
View original content: http://www.newswire.ca/en/releases/archive/September2017/08/c1020.html